PUBLICATION
CD24+CD44+CD54+EpCAM+ gastric cancer stem cells predict tumor progression and metastasis: clinical and experimental evidence
- Authors
- Gómez-Gallegos, A.A., Ramírez-Vidal, L., Becerril-Rico, J., Pérez-Islas, E., Hernandez-Peralta, Z.J., Toledo-Guzmán, M.E., García-Carrancá, A., Langley, E., Hernández-Guerrero, A., López-Casillas, F., Herrera-Goepfert, R., Oñate-Ocaña, L.F., Ortiz-Sánchez, E.
- ID
- ZDB-PUB-230205-15
- Date
- 2023
- Source
- Stem Cell Research & Therapy 14: 1616 (Journal)
- Registered Authors
- Keywords
- Cancer stem cells, Gastric cancer, Immunophenotype, Metastasis, Xenotransplants, Zebrafish
- MeSH Terms
-
- Animals
- Biomarkers, Tumor/metabolism
- CD24 Antigen/genetics
- Cell Line, Tumor
- Cohort Studies
- Epithelial Cell Adhesion Molecule/genetics
- Epithelial Cell Adhesion Molecule/metabolism
- Humans
- Hyaluronan Receptors/genetics
- Hyaluronan Receptors/metabolism
- Intercellular Adhesion Molecule-1
- Neoplastic Stem Cells/metabolism
- Precision Medicine
- Stomach Neoplasms*/metabolism
- Zebrafish*/metabolism
- PubMed
- 36737794 Full text @ Stem Cell Res. Ther.
Citation
Gómez-Gallegos, A.A., Ramírez-Vidal, L., Becerril-Rico, J., Pérez-Islas, E., Hernandez-Peralta, Z.J., Toledo-Guzmán, M.E., García-Carrancá, A., Langley, E., Hernández-Guerrero, A., López-Casillas, F., Herrera-Goepfert, R., Oñate-Ocaña, L.F., Ortiz-Sánchez, E. (2023) CD24+CD44+CD54+EpCAM+ gastric cancer stem cells predict tumor progression and metastasis: clinical and experimental evidence. Stem Cell Research & Therapy. 14:1616.
Abstract
Background Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide. Specific and thorough identification of cancer cell subsets with higher tumorigenicity and chemoresistance, such as cancer stem cells (CSCs), could lead to the development of new and promising therapeutic targets. For better CSC identification, a complete or extended surface marker phenotype is needed to provide increased specificity for new cell targeting approaches. Our goal is to identify and characterize a putative extended phenotype for CSCs derived from patients with GC before treatment, as well as to evaluate its clinical value. In addition, we aim to ensure that cells with this phenotype have stemness and self-renewal capabilities.
Methods This is a cohort study including 127 treatment-naïve patients with GC who attended the Instituto Nacional de Cancerología. Multiparametric flow cytometry analysis was performed to determine the extended phenotype of cells derived from gastric biopsies. The tumorigenic capability of cells identified in patients was assessed in a zebrafish model.
Results CD24+CD44+CD54+EpCAM+ cells were present in all treatment-naïve patients included, with a median abundance of 1.16% (0.57-1.89%). The percentage of CD24+CD44+CD54+EpCAM+ cells was categorized as high or low using 1.19% as the cutoff for the CD24+CD44+CD54+EpCAM+ cell subset. Additionally, a higher TNM stage correlated with a higher percentage of CD24+CD44+CD54+EpCAM+ cells (Rho coefficient 0.369; p < 0.0001). We also demonstrated that a higher percentage of CD24+CD44+CD54+EpCAM+ cells was positively associated with metastasis. The metastatic potential of these cells was confirmed in a zebrafish model. Ultimately, under our conditions, we conclude that CD24+CD44+CD54+EpCAM+ cells are true gastric cancer stem cells (GCSCs).
Conclusion The CD24+CD44+CD54+EpCAM+ cells present in tissue samples from patients are true GCSCs. This extended phenotype results in better and more specific characterization of these highly tumorigenic cells. The relative quantification of CD24+CD44+CD54+EpCAM+ cells has potential clinical value, as these cells are associated with metastatic disease, making their presence an additional prognostic marker and possibly a target for the design of new antineoplastic treatments in the era of precision oncology. Overall, the extended CD24+CD44+CD54+EpCAM+ phenotype of GCSCs could support their isolation for the study of their stemness mechanisms, leading to the identification of better molecular targets for the development of both new therapeutic approaches such as oncoimmunotherapy and new diagnostic and clinical prognostic strategies for GC.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping